Welcome to Latam Insights! Crypto and Economic News in Latin America Welcome to Latam Insights, your go-to source for the latest news on crypto and economic developments in Latin America. In this weekly issue, we’ll be diving into some of the most relevant stories shaping the region’s financial landscape. From El Salvador to Paraguay and…
The Future of Powered Smart Cards Dublin, Sept. 02, 2024 (GLOBE NEWSWIRE) — The “Powered Smart Cards – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering. The global market for Powered Smart Cards was estimated at US$4.5 Billion in 2023 and is projected to reach US$8.3 Billion by 2030, growing at a CAGR…
Reiterating a ‘Buy’ Rating for IDEX Looking Beyond Near-Term Headwinds Despite facing near-term headwinds in organic revenue and market softness, I firmly believe that IDEX is a strong buy at its current valuation. With a fair price target of $220 per share, the recent acquisition of Mott Corporation for $1 billion has strategically positioned IDEX…
American Public Education (APEI) has seen a significant increase in its stock price, more than tripling in value recently. This surge is attributed to the for-profit educator successfully turning itself around after a challenging acquisition. Despite the substantial growth, there is still room for the stock to rise further, as it currently trades at a…
Recommended Cash Acquisition of Trident Royalties PLC by Deterra Global Holdings Pty Ltd Scheme of Arrangement Becomes Effective On 13 June 2024, the boards of Deterra Global Holdings Pty Ltd (“Bidco”) and Trident Royalties Plc (“Trident”) announced that they had agreed the terms of a recommended cash acquisition of Trident by Bidco. This acquisition will…
Breaking News: Tolebrutinib Triumphs in HERCULES Phase 3 Trial – A Groundbreaking Treatment for Non-Relapsing Secondary Progressive Multiple Sclerosis! Description: Tolebrutinib has met the primary endpoint in the HERCULES phase 3 study, making it the first and only treatment to demonstrate a reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis (nrSPMS) patients. This…
Equifax: A Strong Buy with a One-Year Price Target of $360 Per Share Overview In light of Equifax’s impressive performance in Q2, I reiterate a ‘Strong Buy’ rating for the company with a one-year price target of $360 per share. Equifax has shown robust growth in its non-mortgage businesses, offsetting the decline in mortgage revenue….
Donald Trump has long been criticized for what some have called corrupt foreign practices involving money coming from foreign nations, but those issues are only growing deeper, according to a new report. Before, during, and after his presidency, Trump benefited from foreign deals that largely flew under most citizens’ radar. But those deals are ramping…
